Structure via PubChem · Public domain (PubChem)
laropiprant
Laropiprant (INN) was a drug used in combination with nicotinic acid to reduce blood cholesterol (LDL and VLDL) that is no longer sold, due to increases in side-effects with no cardiovascular benefit. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by nicotinic acid.
Chemical data
- Formula
- C21H19ClFNO4S
- Molecular weight
- 435.9 g/mol
- IUPAC name
- 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- Indications
- rosacea, Hypercholesterolemia, familial hypercholesterolemia, Disorder of lipid metabolism
via ChEMBL · EBI
Wikidata facts
- Mass
- 435.07073498799997
Show 4 more facts
- chemical formula
~3 min read
Article
3 sectionsContents
- Mechanism of action
- History
- References
Laropiprant (INN) was a drug used in combination with nicotinic acid to reduce blood cholesterol (LDL and VLDL) that is no longer sold, due to increases in side-effects with no cardiovascular benefit. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by nicotinic acid.
Merck & Co. planned to market this combination under the trade names Cordaptive in the US and Tredaptive in Europe. Both brands contained 1000 mg of nicotinic acid (niacin) and 20 mg of laropiprant in each tablet.
Available in 7 languages
via Wikidata sitelinks · CC0
Connections
Categories
4-Chlorophenyl compoundsAcetic acidsBenzosulfonesChemical articles with multiple CAS registry numbersChemical articles with multiple PubChem CIDsChemical pages without DrugBank identifierChemicals using indexlabelsCombination lipid-lowering drugsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA link